|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2007-8-31
|
|
pubmed:abstractText |
BMS-310705, a water-soluble semi-synthetic analogue of epothilone B, was selected for clinical development because of its in vivo anti-tumour activity and toxicity profile similar to that of ixabepilone, currently the most extensively evaluated and promising epothilone B analogue. The improved solubility of BMS-310705 allowed a cremophore-free formulation that avoided the need for pre-medication.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1548-53
|
|
pubmed:meshHeading |
pubmed-meshheading:17761711-Adult,
pubmed-meshheading:17761711-Aged,
pubmed-meshheading:17761711-Antineoplastic Agents,
pubmed-meshheading:17761711-Diarrhea,
pubmed-meshheading:17761711-Drug Administration Schedule,
pubmed-meshheading:17761711-Epothilones,
pubmed-meshheading:17761711-Female,
pubmed-meshheading:17761711-Humans,
pubmed-meshheading:17761711-Male,
pubmed-meshheading:17761711-Middle Aged,
pubmed-meshheading:17761711-Neoplasms,
pubmed-meshheading:17761711-Nervous System Diseases,
pubmed-meshheading:17761711-Neutropenia,
pubmed-meshheading:17761711-Tubulin Modulators
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.
|
|
pubmed:affiliation |
IOSI, Bellinzona, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
